SKIN Stock Overview
Designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
The Beauty Health Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.74 |
| 52 Week High | US$5.17 |
| 52 Week Low | US$0.91 |
| Beta | 0.81 |
| 1 Month Change | 19.18% |
| 3 Month Change | 8.75% |
| 1 Year Change | -28.40% |
| 3 Year Change | -87.24% |
| 5 Year Change | n/a |
| Change since IPO | -83.95% |
Recent News & Updates
Recent updates
The Beauty Health Company (NASDAQ:SKIN) Doing What It Can To Lift Shares
Dec 27
Health Check: How Prudently Does Beauty Health (NASDAQ:SKIN) Use Debt?
Oct 18Positive Sentiment Still Eludes The Beauty Health Company (NASDAQ:SKIN) Following 33% Share Price Slump
Aug 06Is There Now An Opportunity In The Beauty Health Company (NASDAQ:SKIN)?
Jul 16Not Many Are Piling Into The Beauty Health Company (NASDAQ:SKIN) Stock Yet As It Plummets 28%
Jun 14Calculating The Fair Value Of The Beauty Health Company (NASDAQ:SKIN)
May 30The Beauty Health Company (NASDAQ:SKIN) Stock Rockets 31% But Many Are Still Ignoring The Company
Feb 16The Beauty Health Company's (NASDAQ:SKIN) Share Price Matching Investor Opinion
Jun 19Is The Beauty Health Company (NASDAQ:SKIN) Trading At A 39% Discount?
May 28At US$13.26, Is The Beauty Health Company (NASDAQ:SKIN) Worth Looking At Closely?
Apr 04Beauty Health's (NASDAQ:SKIN) Earnings Are Of Questionable Quality
Mar 08What Is The Beauty Health Company's (NASDAQ:SKIN) Share Price Doing?
Jan 01An Intrinsic Calculation For The Beauty Health Company (NASDAQ:SKIN) Suggests It's 24% Undervalued
Dec 05The Beauty Health Company: A Compelling Mid To Long-Term Growth Story
Oct 12Beauty-Health Company announces $200M buyback program
Sep 27The Beauty Health Q2 2022 Earnings Preview
Aug 08The Beauty Health Company: Not Looking The Best
Jul 30Shareholder Returns
| SKIN | US Personal Products | US Market | |
|---|---|---|---|
| 7D | 12.3% | 3.1% | 3.2% |
| 1Y | -28.4% | -20.3% | 24.2% |
Return vs Industry: SKIN underperformed the US Personal Products industry which returned -20.3% over the past year.
Return vs Market: SKIN underperformed the US Market which returned 24.2% over the past year.
Price Volatility
| SKIN volatility | |
|---|---|
| SKIN Average Weekly Movement | 11.0% |
| Personal Products Industry Average Movement | 8.4% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 18.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: SKIN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: SKIN's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 881 | Marla Beck | www.beautyhealth.com |
The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company’s flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer’s preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health.
The Beauty Health Company Fundamentals Summary
| SKIN fundamental statistics | |
|---|---|
| Market cap | US$215.97m |
| Earnings (TTM) | -US$28.17m |
| Revenue (TTM) | US$347.62m |
0.6x
P/S Ratio-7.7x
P/E RatioIs SKIN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SKIN income statement (TTM) | |
|---|---|
| Revenue | US$347.62m |
| Cost of Revenue | US$171.98m |
| Gross Profit | US$175.64m |
| Other Expenses | US$203.81m |
| Earnings | -US$28.17m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.23 |
| Gross Margin | 50.53% |
| Net Profit Margin | -8.10% |
| Debt/Equity Ratio | 923.3% |
How did SKIN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/19 11:51 |
| End of Day Share Price | 2025/01/17 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
The Beauty Health Company is covered by 15 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bruce Jackson | Benchmark Company |
| Navann Ty Dietschi | BNP Paribas Exane |
| Kyle Rose | Canaccord Genuity |